Menstrual Migraine
Conditions
Brief summary
The objective of this phase 2 Proof.of Concept study is to evaluate the efficacy and safety of Sepranolone (UC1010) in preventing menstrual migraine attacks in adult women with migraine occurring between Day -2 and Day 5 of the menstrual cycle. Patients will be taking Sepranolone or Placebo (blinded to patient and study doctor) during the two week preceding the menstruation for three menstrual cycles. Effect (change from baseline) will be assessed by comparison of symptoms recorded daily by the patients using an electronic diary using validated scales for assessment of menstual migraine symptoms. Sepranolone is identical to an endogenous steroid.
Detailed description
The objective of this phase 2 Proof-of-Concept study is to evaluate the effect and safety of two doses of Sepranolone (UC1010) in preventing menstrual migraine attacks in adult women with migraine occurring between Day -2 and Day 5 of the menstrual cycle in comparison to placebo. Study treatment will be self-administrated as subcutaneous injections during the luteal phase of three consecutive menstrual cycles. Effect will be assessed by comparison of symptoms recorded daily by the patients using an electronic migraine diary and a validated rating scale for assessment the physical and functional impact of menstrual migraine symptoms (MPFID). Preceding the treatment period, the diagnosis of Menstrual Migraine will be established by verifying menstrual migraine in at least two out of three menstrual cycles of daily symptom ratings by the patients. This period will also constitute the baseline data. The effect of study medication will be assessed as the change in symptoms from baseline to during treatment. The reduction in average number of menstrual migraine days per menstrual cycle during the treatment period cycles vs. the three menstrual cycles of baseline will constitute the primary endpoint. The study will also include a follow-up (no treatment) cycle before patients final visit. The study is conducted in three European countries (Sweden, Finland and Denmark) and will randomize 84 patients.
Interventions
DRUGSepranolone injection low dose
Subcutaneous (SC) administration
DRUGSepranolone injection high dose
Subcutaneous (SC) administration
DRUGPlacebo injection
Subcutaneous (SC) administration
Sponsors
Asarina Pharma
Aurevia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 48 Years
Healthy volunteers
No
Inclusion criteria
* have Menstrual Migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) verified in three menstrual cycles * have a regular menstrual cycle of 24-35 days cycle, * use double barrier contraception, intrauterine device (IUD), be truly sexually abstinent, or subject or her partner has been surgically sterilized,
Exclusion criteria
* More than 10 headache days per month on average during screening phase * steroid hormonal treatment during previous three months * ongoing treatment with antiepileptic drugs or benzodiazepines * significant medical or psychiatric condition * be pregnant or plan a pregnancy within the study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in number of menstrual migraine days | Through study completion, an average of 6 months | Change from baseline in the average number of menstrual migraine days during three consecutive menstrual cycles |
Countries
Finland, Sweden
Outcome results
None listed